AI to drive personalized medicine outsourcing to $281Bn by 2032: SNS
TEXAS, UNITED STATES — Fueled by breakthroughs in artificial intelligence (AI) and genomics, the global personalized medicine outsourcing market is on track to reach $281.72 billion by 2032, according to a report from SNS Insider.
The study projects the market will grow from $109.88 billion in 2024 to nearly $282 billion by 2032, marking a compound annual growth rate (CAGR) of 12.54 percent between 2025 and 2032.
Analysts attribute this rapid expansion to the combined power of AI-driven analytics, genomic research, and strategic outsourcing partnerships that are transforming drug discovery and development worldwide.
AI and genomics transform personalized medicine R&D
The demand for personalized treatments is surging as healthcare systems pivot toward precision-based care.
Biopharma companies are increasingly partnering with contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and diagnostic service providers to accelerate R&D, optimize production, and cut costs.
In the United States, the market was valued at USD 30.61 billion in 2024 and is forecast to reach USD 77.07 billion by 2032, underscoring North America’s dominance driven by advanced healthcare infrastructure and robust R&D investment.
The oncology segment continues to lead the field, accounting for 55.2% of the market in 2024, driven by rising cancer incidence and the growing effectiveness of targeted therapies.
Major industry players such as Syngene International, Infosys, and HCL Technologies are helping shape this landscape.
These firms are leveraging digital platforms, bioinformatics tools, and cloud-based solutions to support personalized medicine research, data management, and large-scale manufacturing collaborations.
North America leads, Asia-Pacific gains ground
North America remains the global hub for personalized medicine outsourcing, accounting for 36.6% of the market in 2024, while Asia-Pacific is emerging as the fastest-growing region due to expanded clinical trial activity and rising pharmaceutical production capacity.
The contract manufacturing segment currently holds the largest market share, driven by demand for scalable production of cell and gene therapies.
However, the contract development segment is projected to expand at the fastest pace, as drug pipelines become more complex and demand specialized expertise.
Strategic outsourcing drives biotech innovation
This accelerating trend in personalized medicine outsourcing mirrors broader movements across the global biopharmaceutical outsourcing industry, where companies are leaning on specialized partners to enhance flexibility and manage risk.
As therapies become more tailored and data-driven, outsourcing offers a way to efficiently scale innovation—positioning contract organizations as vital allies in the future of precision healthcare.
In essence, the $281 billion boom isn’t just about market size—it’s a reflection of how AI, genomics, and strategic outsourcing are converging to redefine modern medicine.
